Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872715 · ClinicalTrials.gov registry record · Phase 4
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
A Phase 4 study of Papulopustular Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01872715: Completed Phase 4 study of Papulopustular Rosacea, sponsored by Galderma R&D.
NCT01872715 is a Phase 4 study of Papulopustular Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 24 participants, below the 277-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01872715, a Phase 4 study of Papulopustular Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
Primary Outcome
VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable
Conditions Studied
Interventions
- DRUG Oracea
Study Locations (1)
Texas
- Stephens & Associates Dallas Research Center - Carrollton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
What the finished NCT01872715 record still lists
NCT01872715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 277-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Oracea is the first listed.
NCT01872715 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01872715 about?
NCT01872715 is a clinical study titled "Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea". The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
What is the current status of trial NCT01872715?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2013-03. Estimated completion is 2013-06.
What conditions does trial NCT01872715 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT01872715?
The interventions under investigation include: Oracea (DRUG).
Who is sponsoring clinical trial NCT01872715?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01872715 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01872715's enrollment target sits among peer trials
24 9th of 11 higher than 3 of 11 other Papulopustular Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Papulopustular Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
COMPLETED · Phase 4
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia